- Sales +9% and EBIT +11% vs. ABGSCe - Organic growth of +14%, better than ABGSCe +5% - Likely to se...
Redeye will likely increase its Base Case and forecasts following a strong Q2 report, with solid imp...
Redeye lowered its Base Case and forecasts somewhat following a Q2 report on the somewhat soft side,...
- Q2: 8% organic sales growth, but adj. EBITA down 6% y-o-y - Platform & Sportsbook signings have be...
Plejds nettoomsättning för det andra kvartalet 2024 uppgick till 146,2 MSEK (110,3), en ökning med 3...
Redeye has updated its estimates for Carasent following the Q2 2024 report, which was quite undramat...
- Q2e: lower top-line y-o-y, but strong GM supports EBIT - EBIT down 5-4% on slower assumed market r...
XVIVO delivered an organic growth surprise at 32% (CER, 32% in Q1) during Q2 a quarter, with a subst...
Redeye recognizes that volatile sales over quarters are currently an issue for the share performance...
- Q2e: Slight margin improvements expected - Org. estimates mostly unchanged, EBITA down 2-3% on FX ...
Redeye updates its estimates and valuation following Vitec releasing its Q2 2024 report.
Redeye makes negligible estimate revisions on the back of Climeon’s Q2 figures which was in line wit...
Elanders presented a decent Q2 2024 report with flat organic sales y/y, partly supported by easier c...
Atria raised its guidance on 12 July. The company now expects its adjusted EBIT to improve from 2023...
Redeye takes a positive stance towards Fortnox following an overall solid Q2 report, with strong gro...
- Q2: stable top line despite headwinds, margins keep improving y-o-y - Tweaked '24e, as we look for...
- Q2 showed turnaround in organic growth... - ...and confirmed demand trough - Low valuation and in ...
Atria raised its adjusted EBIT guidance and now expects growing earnings in 2024 (earlier: adjusted ...
Redeye sees a Q2 report coming in below our expectations on margins and EBITA, as all three Division...
- Q2 sales a touch above our ests. at SEK 229m, for 7% org.
